# HER2+ Cancers This page is the **deeper mechanism page** behind the shorter question page on whether **HER2+/ERα+** patients should avoid **resveratrol or polydatin**. If you want the practical answer first, start here: * [Should HER2+/ERα+ Patients Avoid Resveratrol or Polydatin?](/myhealingcommunity-docs/breast-cancer/her2-positive/should-her2+-era+-patients-avoid-resveratrol-or-polydatin.md) This page goes deeper into **why the caution exists**, **where the evidence comes from**, and **where its limits begin**. ### Short answer first The current concern is strongest in **HER2-positive breast cancer**, not in all HER2-positive cancers generally. More specifically, it is strongest in **HER2-positive, ER-positive breast cancer** where **Luminal B-like** or **triple-positive** biology may overlap with the **Δ16HER2 / resveratrol** signal. That is why this page should be read as a **breast-cancer-specific caution page**, not a blanket HER2-wide rule. ### What is Δ16HER2? Δ16HER2 is an oncogenic splice variant of HER2. It is not the same as routine HER2 overexpression alone. It has been described especially in **breast cancer**, where it has been linked to aggressive behaviour and trastuzumab resistance. ### Why it matters for polydatin Polydatin is metabolised toward resveratrol. The caution comes from evidence that **resveratrol** accelerated tumour growth in a **Δ16HER2 transgenic breast-cancer mouse model** rather than inhibiting it. That matters because **polydatin is not a separate universe from resveratrol**. It is a related compound with its own biology, but it also feeds into the resveratrol story through metabolism. That means the concern is not a generic statement that polydatin is unsafe in every HER2-positive cancer. It is a specific mechanistic warning that becomes most relevant when discussing **HER2-positive breast cancer**, especially when **ERα signalling** is still active and **Δ16HER2 biology** may be present. ### What this page adds beyond the shorter HER2+ answer page The shorter page gives the clean practical conclusion. This page adds three things: * the **Δ16HER2** background * the reason the warning is **breast-cancer-specific** * the limits of the evidence, so the caution is not overstated For the wider breast-cancer evidence on polydatin itself, also see [Breast Cancer](/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/polydatin-evidence-by-cancer-type/breast-cancer.md). ### What we can and cannot say honestly #### What we can say * There is a real peer-reviewed signal of concern in a Δ16HER2 breast-cancer model * Because polydatin converts toward resveratrol, this deserves clinician review in HER2-positive breast cancer * The concern is important enough that it should not be buried or dismissed #### What we cannot say confidently * We cannot say this applies to **all HER2-positive cancers** * We cannot say every HER2-positive tumour has clinically relevant Δ16HER2 expression * We cannot say this has been confirmed in human oncology trials ### Practical interpretation for readers For readers with **HER2-positive breast cancer**, polydatin should not be treated as a casual self-directed adjunct. The combination of: * possible direct mechanistic benefits from polydatin * possible cardioprotective rationale in some treatment settings * and the unresolved **Δ16HER2 / resveratrol** concern means this belongs in a discussion with the treating oncologist. For readers who arrived here from the shorter question page, this is the main reason that page lands on **"discuss first"** rather than offering quick reassurance. For other HER2-positive cancers, the evidence is not strong enough to automatically extend the same warning without saying clearly that the current **Δ16HER2** concern is mainly **breast cancer-based**. This is best framed as a **HER2-positive breast cancer caution**, not a blanket HER2-wide rule.\ \ If you want the deeper paper-level breakdown, use the expandable section below.
Deep dive: Resveratrol, Δ16HER2, and the Luminal B breast cancer caution ### What the key paper showed The 2017 Andreani/Bartolacci study investigated resveratrol in a **Δ16HER2 transgenic breast-cancer model**. Instead of suppressing tumour growth, resveratrol accelerated tumour development in that specific model. Main findings included: * earlier tumour onset in resveratrol-treated mice * higher tumour number per mouse * higher proliferative signalling * accumulation of Δ16HER2 protein after partial proteasome inhibition * preferential Δ16HER2/HER3 pairing * activation of the mTORC1/p70S6K/4EBP1 pathway * marked reduction in ERα expression ### Why the subtype matters Δ16HER2 is a splice variant of HER2 that has been described especially in **HER2-positive breast cancer**, particularly where aggressive behaviour and trastuzumab resistance are concerns. This is why the caution is strongest in **HER2-positive breast cancer**, especially Luminal B-style biology, rather than being extended casually to every HER2-positive cancer. ### Important limits of the evidence This is a real and mechanistically detailed paper, but it still has limits: * small animal groups * no decisive human clinical replication * uncertain human dose translation * strongest relevance in a specific breast-cancer subtype context So the right conclusion is not panic and not dismissal. The right conclusion is **honest caution**. ### Practical takeaway from the deep dive Readers with **HER2-positive and ER-positive breast cancer** should discuss this specifically with their oncologist before using higher-dose resveratrol or polydatin. Readers with other HER2-positive cancers should not assume the same warning applies in the same way, because the strongest current evidence is breast-cancer specific.
### Related pages * [Should HER2+/ERα+ Patients Avoid Resveratrol or Polydatin?](/myhealingcommunity-docs/breast-cancer/her2-positive/should-her2+-era+-patients-avoid-resveratrol-or-polydatin.md) — short practical answer * [Breast Cancer](/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/polydatin-evidence-by-cancer-type/breast-cancer.md) — wider polydatin breast-cancer evidence * [Triple-Positive](/myhealingcommunity-docs/breast-cancer/triple-positive.md) — overlap between HER2 and hormone-receptor biology * [Distinguishing Luminal A from Luminal B](/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/distinguishing-luminal-a-from-luminal-b.md) — subtype context for this caution ### References Resveratrol fuels HER2 and ERα-positive breast cancer behaving as an oncogenic compound in Δ16HER2 transgenic mice — Andreani, Bartolacci et al., Aging, 2017\ The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers — comprehensive review, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Cancers, 2019\ HER2 isoforms co-expression differently tunes mammary tumour phenotypes — companion paper from same research tradition, PMC, 2017\ Combination treatment with PI3K/AKT/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer\ {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/polydatin-evidence-by-cancer-type/her2+-cancers.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.